EyePoint Names Tarek S. Hassan, MD, as SVP and Chief Strategic Science Officer
WATERTOWN, Mass.—EyePoint, Inc. (Nasdaq: EYPT), a clinical-stage biopharmaceutical company and developer of therapeutics for patients with serious retinal diseases, has announced the appointment of Tarek S. Hassan, MD, as senior vice president, chief strategic science officer. Dr. Hassan will report directly to Jay S. Duker, MD, president and CEO of EyePoint, and will serve as a member of the exec
July 14, 2026